Following my earlier post on this issue, it is now reported that the Indian Patent Office (IPO) has refused patent to the anti-cancer drug, Abraxane. I am yet to obtain a copy of this IPO order.
A recap
Briefly, the opposition against the patent application for Abraxane was filed by Natco Pharma with the IPO and was decided against the patent applicant, Abraxis Biosciences (“Abraxis”). Abraxis appealed against the IPO’s order with the Intellectual Property Appellate Board (IPAB) owing to certain procedural lapses. IPAB agreed with Abraxis and asked the IPO to consider the opposition afresh.
What’s new?
The recent order of the IPO is said to have stated the following:
“The amended claims (here Abraxis Boisciences) lack inventive step and do not constitute an invention under the Patents Act, 1970.”
I will update this post and discuss the IPO’s order in detail once I peruse the order.
Raja Selvam
Founder & Managing Attorney, Selvam & Selvam | Practice areas include Trademarks, Patents, Domain names & Business law. Visiting faculty, Department of Journalism, Madras University where I teach copyrights & trademarks law. Passionate about entrepreneurship, start-ups, stocks, farming, technology and law.
Indian Trademarks Office goes the paperless way!
For those of you who use (and love, maybe?) the e-filing system (“system”) of the Trademarks Office, things just got lovelier. Until the evening of…
What does it mean when a TM-61 alert is issued for my trademark application by the Indian Trademark Office?
If you had filed your trademark application on paper in India with specification of goods or services exceeding 500 characters and if an application…
Protection of Plant varieties in India: lack of choices?
Any person as described under Sec.16 of the Act can apply for the registration of a new variety of plant with the Office of the Registrar, Protection…